Mobia Medical is a commercial-stage medical device company focused on redefining stroke recovery for survivors with motor impairments. The company's flagship product, the Vivistim Paired Vagus Nerve Stimulation (Paired VNS) System, is designed to enhance recovery outcomes for stroke patients. Mobia Medical aims to address a significant healthcare burden associated with ischemic strokes through innovative technology.
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $32.0B | $15.6B |
| YoY Growth | +105.1% | - |
| Adjusted Net Loss | -$46.5M | -$24.6M |
| Margin % | -0.1% | -0.2% |
Based on price range midpoint and most recent fiscal year data.
The company operates in the medical device industry, specifically targeting stroke recovery solutions. Mobia Medical competes with companies such as MicroTransponder and others in the neurostimulation market.
Proceeds from the IPO are expected to be utilized for general corporate purposes, which may include funding research and development, working capital, and potential acquisitions.
No broker information available yet
Check back later for updates
Reported by users or publicly disclosed. Information is for reference only.